| Sign In to gain access to subscriptions and/or personal tools. |
Cholinesterase status, pharmacokinetics and laboratory findings during obidoxime therapy in organophosphate poisoned patientsWalther-Straub-Institut für Pharmakologie und Toxikologie der Ludwig-Maximilians-Universität München, Nußbaumstraße 26, D-80336 München
Walther-Straub-Institut für Pharmakologie und Toxikologie der Ludwig-Maximilians-Universität München, Nußbaumstraße 26, D-80336 München
Walther-Straub-Institut für Pharmakologie und Toxikologie der Ludwig-Maximilians-Universität München, Nußbaumstraße 26, D-80336 München
Walther-Straub-Institut für Pharmakologie und Toxikologie der Ludwig-Maximilians-Universität München, Nußbaumstraße 26, D-80336 München
Toxikologische Abt. der . Med. Klinik der Technischen Universität München, Ismaningerstraße 22, D-81664 München, Germany
Toxikologische Abt. der . Med. Klinik der Technischen Universität München, Ismaningerstraße 22, D-81664 München, Germany
Toxikologische Abt. der . Med. Klinik der Technischen Universität München, Ismaningerstraße 22, D-81664 München, Germany
Toxikologische Abt. der . Med. Klinik der Technischen Universität München, Ismaningerstraße 22, D-81664 München, Germany 1 The effectiveness of oxime therapy in organophos phate poisoning is still a matter of debate. It appears, however, that the often cited ineffectiveness of oximes may be due to inappropriate dosing. By virtue of in vitro findings and theoretical considerations we concluded in the preceding paper that oximes should preferably be administered by continuous infusion following an initial bolus dose for as long as reactiva tion of inhibited acetylcholinesterase (AChE) can be expected. This conclusion has called for a clinical trial to evaluate such oxime therapy on the basis of objective parameters. 2 Before transfer to the intensive care unit (ICU), 5 patients received primary care by an emergency physician. In the ICU, atropine sulphate was adminis tered IV upon demand according to the endpoints: no bronchorrhoea, dry mucous membranes, no axillary sweating, heart rate of about 100/min. Obidoxime (Toxogonin®) was given as an IV bolus (250 mg) followed by continuous infusion of 750 mg/24 h. 3 Intoxication and therapy were monitored by determin ing erythrocyte AChE (eryAChE) activity, reactivat ability of the patient's eryAChE ex vivo, plasma cholinesterase activity, the presence of AChE inhibit ing compounds, as well as the concentrations of obidoxime and atropine in plasma. 4 Obidoxime was effective in life-threatening parathion poisoning, in particular when the dose absorbed was comparably low. In mega-dose poisoning, net reacti vation was not achieved until several days after ingestion, when the concentration of active poison in plasma had declined. Reactivatability in vivo lasted for a longer period than expected from in vitro experiments. 5 Obidoxime was quite ineffective in oxydemeton- methyl poisoning, when the time elapsed between ingestion and oxime therapy was longer than 1 day. When obidoxime was administered shortly after ingestion (1 h) reactivation was nearly complete. 6 Obidoxime levels of 10-20 µM were achieved by our regimen, and atropine could rapidly be reduced to approx. 20 nM, as attained by continuous infusion of 1 mg atropine sulphate/h. Maintenance of the desired plasma levels was not critical even when renal function deteriorated. 7 Signs of transiently impaired liver function were observed in patients who showed transient multi- organ failure. In the present stage of knowledge, we feel it advisable to keep the plasma concentration of obidoxime at 10 - 20 µM, although the full reactivating potential of obidoxime will not then be exploited. Still, the reactivation rate, with an apparent half-time of some 3 min, is twice that estimated for a tenfold higher pralidoxime concentration.
Key Words: obidoxime • atropine • acetylcholinesterase • parathion • oxydemeton-methyl • patients • kinetics
Human & Experimental Toxicology, Vol. 16, No. 8,
473-480 (1997) This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
